| Business Summary | | LION
bioscience
AG
(LION)
provides
information
and
knowledge
management
solutions
to
significantly
improve
life
science
research
and
development
(R&D)
performance
and
productivity.
These
solutions
integrate
all
R&D
disciplines,
spanning
from
genetics
to
early
and
late
discovery
through
clinical
trials.
LION
offers
these
solutions
via
two
primary
lines
of
business,
i-biology
and
iD3.
i-biology
involves
the
installation
and
implementation
of
enterprise-wide
horizontal
information
and
knowledge
management
solutions
as
part
of
LION's
Life
Science
Informatics
(LSI)
line
of
business.
Integrated
Drug
Discovery
and
Diagnostics
(iD3)
involves
the
application
of
i-biology
to
LION's
internal
drug
discovery
program
with
the
goal
to
out-license
specific
databases,
polymorphism
marker
panels,
and
validated
targets
and
leads. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | LION
bioscience
AG
is
a
developer
of
enterprise-wide
R&D
data
analysis
and
information
management
systems
and
solutions
for
the
life
sciences
and
healthcare
industry,
enabling
the
use
of
IT
for
drug
discovery.
For
the
fiscal
year
ended
3/31/01,
revenues
totaled
EUR23.3
million,
up
from
EUR10.2
million.
Net
loss
rose
90%
to
EUR23.9
million.
Results
reflect
increased
research
and
development
fees
from
Bayer,
offset
by
increased
personnel
and
preferred
conversion
costs. Recent Earnings Announcement For
the
3
months
ended
06/30/2001,
revenues
were
8,900;
after
tax
earnings
were
-13,100. (Preliminary; reported in thousands of Euro.) | More
from
Market Guide: Significant
Developments |
| Officers | |
| Position | Friedrich Von Bohlen, Ph.D. | Chairman,
CEO | Klaus Sprockamp | CFO,
Chief Operating Officer | Jan Mous | CSO |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|